Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 6, 1997, Pages 763-771

  Adachi, Hideyuki ^a   Tanaka, Hiroshi ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Cardiohemodynamics; Cyclic AMP; Heart failure; Olprinone; Phosphodiesterase III inhibitor; Pig

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CARDIOTONIC AGENT; CATECHOLAMINE; CYCLIC AMP; CYCLIC GMP; LOPRINONE; PHOSPHODIESTERASE INHIBITOR; RENIN;

ADRENERGIC SYSTEM; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEMODYNAMICS; HORMONE BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; CYCLIC AMP; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HORMONES; HUMANS; IMIDAZOLES; MALE; PHOSPHODIESTERASE INHIBITORS; PYRIDONES; STROKE VOLUME; SWINE; VASCULAR RESISTANCE; VENTRICULAR FUNCTION, LEFT;

EID: 0030852846     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199706000-00009     Document Type: Article

References (30)

1. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R, for the Milrinone Multicenter Trial Group. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-83.
2. Packer M, Carver JR, Rodeheffer RJ, et al., for the PROMIS Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
3. Uretskey BF, Jessup M, Konstam MA, et al., for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared with placebo. Circulation 1990;82:774-80.
4. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure: dose-response relationships and comparison to nitroprusside. J Clin Invest 1985;75:643-9.
5. Borow KM, Come PC, Neumann A, Bairn DS, Braunwald E, Grossman W. Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease. Am J Cardiol 1985;55:1204-9.
6. Ludmer PL, Wright RF, Arnold JMO, Ganz P, Braunwald E, Colucci WS. Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation 1986;73:130-7.
7. Ogawa T, Ohhara H, Tsunoda H, Kuroki J, Shoji T. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate: first communication: studies on isolated guinea pig cardiac muscles. Arzneimittelforschung 1989;39(I):33-7.
8. Ohhara H, Ogawa T, Takeda M, Katoh H, Daiku Y, Igarashi T. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate: second communication: studies in dogs. Arzneimittelforschung 1989;39(I):38-45.
9. Sasayama S, Asanoi H, Ishizaka S. Mechanics of contraction and relaxation of the ventricle in experimental heart failure produced by rapid ventricular pacing in the conscious dog. Eur Heart J 1991;12(suppl C):35-41.
10. Tanio H, Kumada T, Hayashi M, Himura Y, Nakamura Y, Kawai C. Hemodynamic efficacy of E-1020 in comparison with dopamine on acute mitral regurgitation in anesthetized digs. Jpn Circ J 1991;55:1068-76.
11. Takaoka H, Takeuchi M, Odake M, et al. Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseased human heart. J Am Coll Cardiol 1993;22:598-606.
12. Whipple GH, Sheffield LT, Woodman EG, Theophilis C, Friedman S. Reversible congestive heart failure due to chronic rapid stimulation of the normal heart. Proc N Engl Cardiovasc Soc 1962;20:39-40.
13. Riegger AJG, Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin Sci 1982;62:465-9.
14. Armstrong PW, Stopps TP, Ford SE, deBold AJ. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation 1986;74:1075-84.
15. Fitzpatrick MA, Nicholls MG, Espiner EA, Ikram H, Bagshaw P, Yandle TG. Neurohumoral changes during onset and offset of ovine heart failure: role of ANP. Am J Physiol 1989;256:H1052-9.
16. Spinale FG, Hendrick DA, Crawford FA, Smith AC, Hamada Y, Carabello BA. Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol 1990;259:H218-29.
17. Wilson JR, Douglas P, Hickey WF, et al. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation 1987;75:857-67.
18. Calderone A, Bouvier M, Li K, Juneau C, Champlain J, Rouleau J-L. Dysfunction of the β- and α-adrenergic systems in a model of congestive heart failure: the pacing-overdrive dog. Circ Res 1991;69:332-43.
19. Marzo KP, Frey MJ, Wilson JR, et al. β-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing. Circ Res 1991;69:1546-56.
20. Perreault CL, Shannon RP, Komamura K, Vatner SF, Morgan JP. Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J Clin Invest 1992;89:932-8.
21. Hirata Y, Ishii M, Matsuoka H, et al. Plasma concentrations of α-human atrial natriuretic polypeptide and cyclic GMP in patients with heart disease. Am Heart J 1987;113:1463-9.
22. Ogawa K, Shiozu H, Mizuno K, Ban M, Ito T, Satake T. Increased plasma cyclic nucleotide concentrations in congestive heart failure. Br Heart J 1984;52:524-9.
23. Arnal JF, Warin L, Michel JB. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 1992;90:647-52.
24. Arnal JF, Amrani AIE, Michel JB. Atrial natriuretic factor influences in vivo plasma, lung and aortic wall cGMP concentrations differently. Eur J Pharmacol 1993;237:265-73.
25. Hamet P, Pang SC, Tremblay J. Atrial natriuretic factor-induced egression of cyclic guanosine 3′:5′-monophosphate in cultured vascular smooth muscle and endothelial cells. J Biol Chem 1989;264:12364-9.
26. Endoh M. Pharmacology of loprinone (E-1020), a new pyridinone inodilator, as a therapeutic agent for acute heart failure. Cardiovasc Drug Rev 1993;11:432-50.
27. Alousi AA, Canter JM, Fort DJ. The beneficial effect of amrinone on acute drug-induced heart failure in the anaesthetized dog. Cardiovasc Res 1985;19:483-94.
28. Sato S, Momose K, Saitoh C, et al. Effects of milrinone on systemic hemodynamics and plasma catecholamine levels in conscious dogs with heart failure. Jpn J Pharmacol 1996;71(suppl I):22.
29. Vatner DE, Sato N, Uechi M, Asai K, Ishikawa Y. Mechanisms of milrinone desensitization in heart failure. Circulation 1996;94:I-360-1.
30. Ohhara H, Sawada K, Ogawa T, Takeda M, Igarashi T. Effects of the new cardiotonic agent loprinone hydrochloride (E-1020) on left ventricular diameter in normal and experimental heart failure dogs and its action potential characteristics in isolated guinea pig cardiac muscles and sinus nodes [Abstract in English]. Folia Pharmacol Japon 1992;99:421-33.